CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases - Wikidata - awgldk - TriplyDB

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

http://www.wikidata.org/entity/Q36846646

about

Association of genetic polymorphisms with osteosarcoma risk: a meta-analysis Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival Tissue biomarkers in melanoma patients treated with TIL Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab Future perspectives of prostate cancer therapy.Immunotherapies: the blockade of inhibitory signals.Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients.The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity.Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab.Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma.Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.Checkpoint modulation in melanoma: an update on ipilimumab and future directions.Identification of Novel HLA-A*0201-Restricted CTL Epitopes in Chinese Vitiligo Patients.Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs.Metastatic melanoma: the new era of targeted therapy.Next-generation peptide vaccines for advanced cancer.Preclinical vaccines against mammary carcinoma.Therapeutic vaccines for cancer: an overview of clinical trials.Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.Engineering of a self-adjuvanted iTEP-delivered CTL vaccine.Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients.Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy.Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase.Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors.Current challenges for cancer vaccine adjuvant development.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections.NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.CTLA-4 (CD152) enhances the Tc17 differentiation program

P2860

Q26797065-C3D8DD97-9110-42EA-991B-9BDE205DC9C9 Q28730798-B27F8B5B-85A1-46A1-AF28-40AEE0367A3C Q33606137-6A437BD2-108A-4248-B32C-B408E29DD060 Q34353251-11AC99E3-6088-4378-A932-0DF00430C960 Q34531444-A9B9AE8F-352D-496C-A852-66E62D5BF26F Q34824109-7DF188B5-909E-42AA-AAE8-F637D9A91EEF Q35289145-1754EEB3-3FCE-4ECF-B163-C06B8BC64784 Q36076453-F9781FB8-2363-45F8-AC0E-E1E8EA50A031 Q36431677-93E7EF83-3A7C-49B9-B784-7331DD20F720 Q36597942-F5DB25B5-FFFA-478B-AD1B-5D5044424691 Q36694921-6DDD5733-F18C-454B-84B2-CB305F86C6DE Q36711007-09944BFD-28A9-4D67-996D-1F92F618478B Q36938806-82D1B243-40A9-4FE0-BE76-2C7F8EF0E800 Q36980597-4F097E75-1169-4639-8B21-4A865F9D7FF4 Q37014061-4810531D-2247-4971-A133-C90E934D1D8C Q37047061-C0E4182C-46B4-46D3-91D3-5E0BE3D7E472 Q37224609-553A6782-0F6B-4022-ABCE-853A75348820 Q37237761-AE0A5F92-E0CA-4DDD-B658-C1711D86499A Q37399612-21C9B330-E5DC-4F49-99A5-CEFDEAE77C50 Q37447879-C771E04B-0906-4EDF-B434-577F9FC9ADEF Q37996425-5CB04FB6-2F54-475D-A58D-B1B2BBF25F72 Q38056246-D78EF81F-88AF-43B5-91E9-BF7BD4CCF10C Q38160252-F2EFB5BA-CB7D-43B1-8C0F-003D5DD0127F Q38227030-D82C7E31-FC4F-45E6-AA24-7E71729A3EAC Q40065644-DE0B4B6C-625B-43B1-B18D-5A647931C175 Q40248942-0E2FBE2D-202C-4042-A70A-40167C2635DC Q41338250-F6067E20-9EC9-4A09-B8CB-5CE91F1EA03C Q41983246-D9A26787-9BAF-4799-8A58-8336DFA9855F Q42375749-C4A77517-562E-40AA-A56C-D7B8E3793EF1 Q44017442-BA659396-B6BB-4F11-83B7-212452F40557 Q47625086-25E7889E-1E9F-4ECA-BE50-B82CBC942256 Q47896312-B735D55D-29F7-4C3B-AFA8-9E6B739CCA76 Q48160317-1F32BC78-C09C-4EC8-AE7E-E992C263AF26 Q48316500-F1C03964-579B-4365-9521-A10FBB8755B9 Q48365640-EA445FA3-A092-4AE4-8F22-B45467AC4C1A Q48891121-60A86025-A3CB-4912-9FDD-5D648F5E2C49 Q50220559-775134EB-EB05-4C1B-9EEF-FF54DAEDD0BB Q50335281-19543B90-9919-4610-ACDB-C90D0FEEC0D0 Q54945263-1A80D011-4F6F-4E66-9D0A-8DD11DAD752A Q56896815-D449F668-F904-487F-831E-8110004DB9E5

P2860

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

http://www.wikidata.org/entity/Q36846646

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

CTLA-4 blockade increases anti ...... nts with melanoma: three cases

@en

type

label

CTLA-4 blockade increases anti ...... nts with melanoma: three cases

@en

prefLabel

CTLA-4 blockade increases anti ...... nts with melanoma: three cases

@en

P1433

Q36846646-C5204D43-721A-4DE4-ADB4-77359CD00053

P1476

Q36846646-6F0F5F40-2FC7-4EFC-ADEC-6AFDA02259A5

P2093

Q36846646-17E373FA-8D7B-45FD-B43D-F2104FAD3FB8

Q36846646-1903DBC5-2E99-4302-9DB6-A0A93005062D

Q36846646-1DF2FA4D-44ED-4518-9B2F-EFE284116E21

Q36846646-2DD5DAAA-89F7-4C24-B99B-A8B727D92E7C

Q36846646-679E8744-182F-49C9-B380-D367AB8B6625

Q36846646-6B555AB8-0A5F-4FCC-B617-90DD6C4021D4

Q36846646-B308AE4E-2DC4-4970-ABA8-A1AEF47603AC

Q36846646-B32620BA-30A0-4F21-8AE8-CEB86485EFE6

Q36846646-B32FF76F-60B0-4518-A46F-87A75F6E8C17

Q36846646-CAB83F49-A374-4D05-BE9B-A28BF20B3341

P2860

Q36846646-0F8EEE19-61CB-4C63-B862-6884A73856DC

Q36846646-21E01166-2F78-4346-88CB-15B3253F53F5

Q36846646-28D20737-69EF-4C6E-B4E8-2C6CC8C68C83

Q36846646-322C9780-47BA-4A44-B8EF-3B9AD9F13251

Q36846646-326DCA3F-1BAE-48B3-979F-310660FDF479

Q36846646-38A695E2-F3AB-4116-BFCE-1DC0BA0E4350

Q36846646-38A9FDD0-AF92-40C9-96C0-DE9AC52B385F

Q36846646-3BFD00A0-7914-4545-93E2-B45A7060E1DA

Q36846646-3F34BD27-61D3-46C6-8D20-9E41FB9F2454

Q36846646-3FBCC0C2-7410-4813-BC0E-E69C7F0E1683

P2888

Q36846646-E5534844-9035-4E82-8C72-0518F9049436

P304

Q36846646-046D5065-4D87-4B6A-B7C7-10DB208279E0

P31

Q36846646-396DDBC5-985E-48FF-8039-3141B38AB241

P356

Q36846646-427DF27A-7048-434B-B011-16223C137DAB

P433

Q36846646-F18A4AED-EA2B-4A7E-B1A1-7B0B1BD831CF

P478

Q36846646-C27228AE-DD01-4346-B094-7B6C09640189

P50

Q36846646-4AA00704-4857-47F2-8228-24F33CE5A97E

Q36846646-5D6D234B-E986-42A3-B095-87E9FC3759B7

Q36846646-766E1F8E-1929-473E-B074-C528405C841D

P577

Q36846646-EE22FA1F-8996-4772-B386-E9FFE50CD860

P5875

Q36846646-ED830FA4-DCA3-4272-8090-49017A753D18

P698

Q36846646-ADD5A542-3E69-46C5-B6AC-DEF3677CCDD6

P932

Q36846646-A411B143-32CD-4B38-8C98-79B76EEA4AF9

P356

S00262-011-1011-9

P1433

Cancer Immunology, Immunotherapy

P1476

CTLA-4 blockade increases anti ...... nts with melanoma: three cases

@en

P2093

Achim Jungbluth

http://www.w3.org/2001/XMLSchema#string

Brian Ginsberg

http://www.w3.org/2001/XMLSchema#string

David Page

http://www.w3.org/2001/XMLSchema#string

Humilidad F Gallardo

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Jianda Yuan

http://www.w3.org/2001/XMLSchema#string

Klaus Busam

http://www.w3.org/2001/XMLSchema#string

Lloyd J Old

http://www.w3.org/2001/XMLSchema#string

Nina Bhardwaj

http://www.w3.org/2001/XMLSchema#string

Teresa Rasalan

http://www.w3.org/2001/XMLSchema#string

P2860

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Cancer statistics, 2008

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

P2888

s00262-011-1011-9

P304

1137-1146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-011-1011-9

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

James P. Allison

P577

2011-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51000506

http://www.w3.org/2001/XMLSchema#string

P698

21465316

http://www.w3.org/2001/XMLSchema#string

P932

3654853

http://www.w3.org/2001/XMLSchema#string